NCT01818362View on ClinicalTrials.gov

A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Seasonal Influenza
Interventions
BIOLOGICAL

MVA NP+M1

MVA NP+M1 1.5 x 10⁸pfu intramuscularly.

BIOLOGICAL

ChAdOx1 NP+M1

ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.

Trial Locations (3)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Oxford

GU2 7XP

Surrey Clinical Research Centre, University of Surrey, Guildford

SO16 6YD

NIHR Wellcome Trust Clinical Research Facility Southampton, Southampton

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01818362 - A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1 | Biotech Hunter | Biotech Hunter